工業和商業黃頁資訊網論文書籍站
南臺科技大學 企業管理系 郭幸萍所指導 張瑜庭的 以科技接受模式探討使用訂房比價網trivago之消費者行為意圖 （2020），提出Ptt MOD關鍵因素是什麼，來自於科技接受模式、使用態度、行為意圖、線上訂房比價網、線上旅遊服務。
而第二篇論文長庚大學 化工與材料工程學系 陳志平所指導 Anilkumar T S的 開發功能化微脂體平台於癌症熱治療 （2020），提出因為有 脂質體、光敏劑、交變磁場、熱療、光熱療法、光動力療法的重點而找出了 Ptt MOD的解答。
Ptt MOD進入發燒排行的影片
【GTA5】徒步環島一圈 要花多久呢?我花4小時你花4分鐘 史詩級加速場面
------------------------------------------
非常感謝您的觀看(Thank you for watching)
希望給我您小小的鼓勵訂閱(Encourage Me ):
https://lihi1.com/EzNBg
【歡迎分享您的遊戲有趣點子與Super泰一起交流】
►Facebook: https://www.facebook.com/superthaivideo/
►Email: [email protected]
-------------------------
想看更多系列:
●GTA5搞笑系列:https://goo.gl/s5kNps
●GTA5彩蛋系列:https://goo.gl/QdJJhY
●GTA5尾隨市民系列:https://goo.gl/hK8ee1
●GTA5深度實驗系列系列:https://goo.gl/uVbnVm
以科技接受模式探討使用訂房比價網trivago之消費者行為意圖
為了解決Ptt MOD 的問題，作者張瑜庭 這樣論述：
科技蓬勃發展，電子商務接二連三出現，改變了原本的商業模式，近幾年自助旅遊風氣興起，國內外線上旅遊服務紛紛進入旅遊市場(例如:airbnb、Booking.com、trivago、kkday 等) ，皆以優惠價格和多元豐富旅遊行程,吸引消費者使用其平臺，因此改變了消費者購買遊程、訂房...等旅遊消費行為。trivago是線上訂房比價網，消費者利用此網站做商品的比價後再進行訂購，以住宿產品為主，讓消費者利用平台線上比價，「用最划算的價格，找到最理想的飯店」，「找飯店? trivago」耳熟能詳的廣告方式頻繁地置入消費者的生活。 本研究目的為探討使用訂房比價網trivago之消費者行為
意圖，研究方法為文獻分析與問卷發放，以科技接受模式(TAM)探討使用消費者使用 trivago 的行為意圖，使用統計軟體進行樣本之資料統計與分析，以系統品質作為科技接受模式的外部變數，探討消費者使用 trivago 的知覺易用性及知覺有用性是否會影響其行為意圖。研究結果顯示trivago平臺的系統品質對知覺有用性與知覺易用性有顯著相關，知覺易用性對知覺有用性有顯著相關，知覺有用性與知覺易用性對使用態度有顯著相關，知覺有用性與使用態度對行為意圖有顯著相關。綜合上述發現，建議trivago積極維護平臺之系統品質，使平臺在使用上能達到易用及有用，提升消費者使用線上旅遊服務平台的意願，為trivago
帶來更多的使用者及效益。
開發功能化微脂體平台於癌症熱治療
為了解決Ptt MOD 的問題，作者Anilkumar T S 這樣論述：
Table of contentsCONTENTS PAGERecommendation letter from thesis advisor……………………..………Thesis/Dissertation oral defense committee certificate……………Acknowledgement iiiChinese abstract viEnglish abstract viiiT
able of contents xiList of figures xviiList of tables xxAbbreviations xxiChapter 1: Overview of Caner Thermal Therapies 11 Introduction 12 Background of thermal therapies 63 Objective 7Chapter 2: Applications of Magnetic Liposomes in Cancer Therapies 91 Introd
uction 91.1. MNPs and liposomes in cancer treatment 101.1.1. Significance of MNPs in cancer therapy 101.1.2. Significance of liposomes in cancer therapy 141.2. Preparation methods of MNPs, liposomes and magnetic liposomes 161.2.1. Preparation methods of MNPs 161.2.1.
1. Physical method 161.2.1.2. Biological method 171.2.1.3. Chemical method 171.2.2. Preparation methods of liposomes 181.2.2.1. Thin film hydration or Bangham method 191.2.2.2. Extrusion method 201.2.2.3. Reverse phase evaporation method 211.2.2.4. Superc
ritical reverse phase evaporation method 211.2.2.5. Detergent depletion method 221.2.2.6. Injection method 231.2.2.7. Microfluidic channel method 241.2.3. Preparation of magnetic liposomes (MLs) 252 Magnetic liposomes in cancer therapies 262.1. MLs for drug delive
ry and thermo-chemotherapy 262.2. MLs for gene delivery and combined gene therapies 312.2.1. MLs for gene delivery 322.2.2. MLs for combined gene therapies 332.3. MLs in photothermal/photodynamic therapy or magneto-phototherapy 342.3.1. Advantages of MLs for targeted ph
otothermal/photodynamic therapy …………………………………………………………………………362.3.2. Use of MLs in photothermal-AMF combined method (magneto-phototherapy) 372.4. Application of MNPs and MLs for cancer imaging and therapy 413 Conclusion 44Chapter 3: Optimization of the Preparation of Magnetic Li
posomes for the Combination Use of Magnetic Hyperthermia and Photothermia in Dual Magneto-Photothermal Cancer Therapy 471 Introduction 472 Materials and Methods 512.1. Materials 512.2. Synthesis of Citric Acid-Coated Iron Oxide Magnetic Nanoparticles (CMNPs) 522.3.
Preparation of Magnetic Liposomes (MLs) 522.4. Experimental Design 532.5. Charactrization of Physico-Chemical Properties 552.6. Heating Efficiency Induced by AMF and/or NIR Laser 562.7. Intracellular Uptake of MLs by Cancer Cells 572.8. In-vitro Biocompatibility of ML
s 592.9. In-vitro Cancer Cell Killing by AMF and/or NIR Laser 592.10. Flow Cytometry Analysis for Apoptosis/Necrosis 602.11. Statistical Analysis 613 Results and Discussion 613.1. Model Development and Optimization 613.2. Characterization of Physico-Chemical Prope
rties 683.3. Heating Efficiency Induced by AMF and/or NIR Laser 783.4. Intracellular Uptake of MLs 803.5. Thermally Induced Cancer Cell Killing In-vitro 824 Conclusion 86Chapter 4: Dual Targeted Magnetic Photosensitive Liposomes for Photothermal/Photodynamic Tumor Therapy
871 Introduction 872 Materials and Methods 902.1. Materials 902.2. Synthesis of citric-acid coated iron-oxide magnetic nanoparticles 912.3. Synthesis of HA-PEG 922.4. Preparation of liposomes 922.5. Determination of encapsulation efficiency of CMNPs and ICG
932.6. Characterization of HA-PEG-MPLs 942.7. Temperature elevation induced by NIR laser irradiation 952.8. In-vitro cell culture experiments 952.9. In-vivo antitumor efficacy 962.10. In-vivo IVIS imaging 982.11. Statistical Analyses 993 Results and Discuss
ion 993.1. Characterization of HA-PEG-MPLs 993.2. In-vitro photothermal effects of HA-PEG-MPLs 1053.3. In-vitro cytotoxicity of HA-PEG-MPLs 1063.4. In-vivo effects of HA-PEG-MPLs 1083.5. In-vivo antitumor and tumor targeting effects from IVIS imaging 1114 Conclusi
on 115Chapter 5: Concurrent Photothermal and Photodynamic Therapy of Intracranial Brain Tumor Xenografts with Convection Enhanced Delivery of Liposomal IR-780 1161 Introduction 1162 Materials and methods 1202.1. Materials 1202.2. Preparation of IR-780 loaded liposomes 1
202.3. Characteristic of IR-780 loaded liposomes (ILs) 1212.4. Photothermal and Photodynamic effects study 1222.5. In vitro cell culture experiments 1232.6. Tumor cell implantation in xenograft mice brain 1252.7. Convection enhanced delivery 1272.8. In vivo temperatu
re measurements during NIR irradiation 1282.9. In vivo anti-tumor efficacy 1292.10. MRI and PET/CT study 1292.11. Bio-distribution 1302.12. Histology studies of tumor tissue 1312.13. Statistical analysis 1323 Results and discussion 1323.1. Characterization o
f ILs 1323.2. In vitro photothermal and photodynamic study 1383.3. In vitro cells experiments 1453.4. In vivo biodistribution 1483.5. In vivo photothermal effects 1503.6. Anti-tumor efficiency 1523.7. MRI and PET-CT studies 1553.8. Immunohistochemical analys
is 1594 Conclusion 163Chapter 6: Conclusions and Outlooks 1641 Summary 1642 Future perspective 165REFERENCES 166List of figuresFigure 2.1 Schematic diagram of MNPs or MLs induced with AMF. 12Figure 2.2 Schematic representations of different kinds of surface modified lip
osomes. 15Figure 2.3 The drug release mechanism from TSMLs 28Figure 2.4 The hyperthermia modality in magneto-phototherapy with MLs induced by MHT with AMF treatment, laser treatment or dual MHT/laser treatments. 38Figure 3.1 The Pareto charts of EE and Size. 65Figure 3.2 Predicted v/s Ob
served value Plots. 66Figure 3.3 Response surface Contour 3D plots. 67Figure 3.4 Particle size and surface charge distribution from DLS and TEM images. 70Figure 3.5 Magnetic liposomes stability measurements with NTA. 72Figure 3.6 XRD, FTIR, SQUID and TGA analysis of CMNP and MLs. 75F
igure 3.7 In vitro heating efficiency of CMNPs and MLs as induced by magnetic hyperthermia (MH) and/or photothermia (PT). 76Figure 3.8 Particle uptake studies with U87 cancer cells. 82Figure 3.9 In-vitro cells biocompatibility and cytotoxicity measurements. 83Figure 3.10 Flowcytometry analy
sis of MLs with different treatments 85Figure 4.1 Schematic illustration of HA-PEG-MPLs for dual targeted photothermal or photodynamic cancer therapy. 90Figure 4.2 Liposomes size from DLS and Cryo-TEM 100Figure 4.3 Characterization of different samples by XRD and FTIR. 102Figure 4.5 The
ex vivo photothermal effects of different samples 105Figure 4.6. The in vitro cell cytotoxicity and live/dead cell assays. 107Figure 4.7 In vivo photothermal effects. 110Figure 4.8 Representative photographs of the tumor-bearing mice 110Figure 4.9 The tumor volume, body weight and surviv
al curve of different groups. 112Figure 4.10 H&E and immunohistochemical analysis in tumor site 112Figure 4.11 The in vivo bioluminescence and fluorescence imaging by IVIS 114Figure 5.1 CED infusion cannulas and their parts 126Figure 5.2 Demonstration mice receiving samples via CED metho
d 127Figure 5.3 schematic diagram of ILs and their characterization 133Figure 5.4 UV-visible and FTIR spectroscopy 134Figure 5.5 Photothermal stability of free IR-780 and ILs 135Figure 5.6 Stability of ILs in FBS measured from nanoparticle tracking analysis. 136Figure 5.7 In-vitro pho
tothermal changes with NIR laser irradiations 139Figure 5.8 Photothermal stability of ILs and Free IR-780 140Figure 5.9 ROS generation detected by UV-visible. 143Figure 5.10 Cell cytotoxicity measurements with MTT and from flow cytometry. 144Figure 5.11 Particle uptake studies with confo
cal laser scanning microscopy. 146Figure 5.12 The bio-distribution analysis of ILs via CED. 149Figure 5.13 in-vivo photothermal effects. 151Figure 5.14 The antitumor efficiency by IVIS, the body weight and survival. 153Figure 5.15 Magnetic resonance images and tumor volume 156Figure 5
.16 PET-CT molecular imaging analysis 158Figure 5.17 H&E and immunohistochemical staining 160Figure 5.18 H&E staining of different organs of mice of all three groups. 161List of tablesTable 2.1 Examples of preparation of magnetic liposomes 25Table 3.1 The central composite design showing
the independent variables and levels used in the experiments 54Table 3.2 Central composite design arrangement and observed responses. 62Table 3.3 Validation of the model with predicated experimental values 65Table 3.4 Size and zeta potentials values. 68Table 3.5 Specific absorption rate
s (SARs) of CMNPs and MLs at 0.6 mg/mL CMNP equivalent1. 73Table 3.6 Apoptotic and necrotic analysis form flow cytometry analysis. 79Table 4.1 Particle size and zeta potential of CMNPs, MPLs and HA-PEG-MPLs. 99Table 5.1 Size and zeta potential values of ILs 129Table 5.2 Survival times of
mice treated in different groups 155Table 5.3 The standardized uptake values (SUVmax) of Ga68-RGD and Ga68-FAPI 159Table 5.4 Hematological parameters and biochemistry analysis in different treatment groups. 162